Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Viatris (VTRS) and Insmed (INSM)

Tipranks - Tipranks - Thu Apr 9, 6:42AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gilead Sciences (GILD), Viatris (VTRS) and Insmed (INSM) with bullish sentiments.

Easter Sale - 70% Off TipRanks

Gilead Sciences (GILD)

In a report released today, Gregory Renza from Truist Financial maintained a Buy rating on Gilead Sciences. The company’s shares closed last Tuesday at $138.80.

According to TipRanks.com, Renza is a 5-star analyst with an average return of 17.8% and a 46.4% success rate. Renza covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Perspective Therapeutics, and Abivax SA Sponsored ADR. ;'>

Gilead Sciences has an analyst consensus of Strong Buy, with a price target consensus of $158.79, representing a 14.2% upside. In a report issued on March 24, Scotiabank also maintained a Buy rating on the stock with a $177.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Viatris (VTRS)

Truist Financial analyst Les Sulewski maintained a Buy rating on Viatris today. The company’s shares closed last Tuesday at $13.16, close to its 52-week high of $13.55.

According to TipRanks.com, Sulewski is a 3-star analyst with an average return of 2.1% and a 43.1% success rate. Sulewski covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Bausch Health Companies, and Pacira Pharmaceuticals. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Viatris with a $15.25 average price target, a 14.5% upside from current levels. In a report issued on March 24, Barclays also maintained a Buy rating on the stock with a $17.00 price target.

Insmed (INSM)

In a report released today, Danielle Brill from Truist Financial maintained a Buy rating on Insmed. The company’s shares closed last Tuesday at $163.03.

According to TipRanks.com, Brill is a 5-star analyst with an average return of 13.7% and a 51.8% success rate. Brill covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Centessa Pharmaceuticals, and Maze Therapeutics, Inc. ;'>

Insmed has an analyst consensus of Strong Buy, with a price target consensus of $216.29, a 32.8% upside from current levels. In a report issued on March 24, TipRanks – Google also upgraded the stock to Buy with a $159.00 price target.

Read More on GILD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).